Set forth below are the names of our directors, executive officers and key consultants and their principal occupations at present and for at least the past five years.
Name Position
William J. FaloonExecutive Chairman of the Board of Directors
Patricia RileyCo-Founder and Director
Maximus V. PetoChief Financial Officer and Director
Douglas F. GassChief Operating Officer
Arthur K. Balin, MD, PhD, FACPChief Medical Director
Alex Zhavoronkov, PhDChief Science Officer
Benjamin BestDirector
James RileyDirector

Our Directors are appointed by the two majority shareholders of our company as provided for in the Shareholders Agreement (as defined herein) and as provided for in our Articles of Incorporation and bylaws and hold office until removed from office in accordance with our bylaws and the Shareholders Agreement. See “Description of Our Securities”. Our officers are appointed by our Board of Directors and hold office until removed by the Board.

William Faloon

Mr. Faloon is a co-founder of the company and was appointed as Chairman of the Board of Directors in July 2016. In 1977, Mr. Faloon founded the Life Extension Foundation (formerly, Florida Cryonics Association), a non-profit corporation that has grown to one of the world’s largest and most recognized organizations relating to longevity research. Since its inception, Life Extension Foundation has contributed over $175 million to a variety of biomedical research initiatives aimed at finding ways to slow aging, better treat degenerative disease, and eliminate involuntary death. Mr. Faloon is a co-founder of Life Extension, a pioneering nutraceutical company recognized as a leader in the field of innovative longevity products. Life Extension provides its clients direct access to comprehensive blood testing and offers a range of complimentary services aimed at keeping clients in the best state of health. In his role at Life Extension, Mr. Faloon writes extensively on the latest research on topics as diverse as how to reduce heart disease, slow systemic aging processes, and reverse dementia.

Patricia Riley
Pat Riley is Co-Founder and Director of the company and initially served as our CEO until December 26th, 2016, prior to Bill Faloon.  Ms. Riley has worked for over 40 years with physicians and scientists in the quest to bring forth products designed to slow aging. She is a scientist and holds ten patents. She is the Founder of Clientele, Inc. and MDR Fitness Corp. and has vast experience developing skin care and nutritional technologies to promote youthful skin and healthy longevity. She cofounded the first stem cell therapeutics workshop at University of Miami. Ms. Riley earned the Jacqueline Kennedy Award, Rising Star of QVC, Northwood University Outstanding Business Leader in 2009, participated in the 1980’s on the Board of Stiefel Laboratories, served as a member of the QVC Vendor Advisory Board from 2003-2006 and was a member of the Northwood University Board of Governors from 2009 to 2013 and the Board of Trustees from 2013 to 2016. Ms. Riley is a Phi Kappa Phi Honor Graduate of the University of Florida, with a Bachelor of Science Degree in Food Science and Nutrition and received a Doctor of Laws (honoris causa) from Northwood University.

Maximus V. Peto

Mr. Peto was appointed as our Chief Financial Officer in July 2016. Since October 2015, Mr. Peto has been a scientific researcher at BioAge Labs, Inc., where he provided scientific database search, curation, project management, and scientific writing services for the company. In addition, Mr. Peto has been a project manager at Life Extension Foundation since June 2015 where he has been involved in the management of research projects on aging and human longevity enhancement and vetting of scientific research proposals for their potential to reverse the degeneration associated with human aging. Concurrently, Mr. Peto has been a Science Literature Analyst at SENS Research Foundation since August 2012 where he screens publications for relevance to SENS Research Foundation research objectives. Mr. Peto also has extensive experience as a protein chemist (2009-2015). Mr. Peto was was previously a college accounting instructor in 2008 and an adjunct college lecturer on international management, business and accounting in 2007. In addition, Mr. Peto has considerable experience as a general, cost, and financial statement accountant (2005-2008). Mr. Peto received a Bachelor of Business Administration from the University of Toledo and a Master of Business Administration from California State University.

Douglas F. Gass

Mr. Gass was appointed as our Chief Operating Officer in July 2016. Mr. Gass has had a diverse career over the last thirty years as a corporate consultant, investment banker, entrepreneur and corporate executive. Since 2010, Mr. Gass has been a member of Flow Capital Advisors, LLC, a business consulting company. From 1991 to 2001 Mr. Gass was a principal and co-founder of M.S. Farrell & Co. Inc., a New York based investment bank. From 1991 to 2001, Mr. Gass has held the position of Vice Chairman and served as a founding board member of Innapharma Inc., a biotechnology company engaged in late stage clinical trials of small chain peptide compounds to treat major depression. During his tenure at Innapharma, the company engaged in several rounds of private equity funding. Mr. Gass holds a Bachelor of Science Degree in Psychology and Business from Flagler College.


Dr. Balin was appointed as our Chief Medical Director in July 2016. Dr. Balin has been engaged in the field of medicine and research for over 45 years and has been interested in understanding the mechanisms that are responsible for the aging process. His research has employed techniques to examine and develop techniques to understand the role of oxygen and oxidative stress in human biology and to ameliorate cutaneous disease associated with the aging process. He served as the Executive Director of the American Aging Association from 1992 – 2008 and he was the Editor-in-Chief of AGE, the scientific Journal of the American Aging Association from 1992 – 2002. Dr. Balin graduated from Northwestern University with Highest Distinction. He went on to complete his MD and PhD in Biochemistry at the University of Pennsylvania where he was a trainee sponsored by the NIH Medical Scientist Training Program. Dr. Balin is currently on staff at the Crozer-Chester Medical Center in Upland, PA and Riddle Memorial Hospital in Media, Pa, and continues to pursue active biomedical aging research in the research facilities of The Sally Balin Medical Center.

Alex Zhavoronkov, PhD

Dr. Zhavoronkov was appointed as our Chief Science Officer in July 2016. Since 2008 he has been the Director and Chief Science Officer of the Biogerontology Research Foundation, a UK-based registered charity supporting aging research worldwide. He is also the CEO or Insilico Medicine, Inc., headquartered at the Emerging Technology Centers at the campus of the Johns Hopkins University in Baltimore. The company is focusing on applying deep learning and advanced signaling pathway activation analysis to drug discovery and drug repurposing for aging and age-related diseases. He is also the director of the International Aging Research Portfolio (IARP) knowledge management project and head of the Regenerative Medicine Laboratory at the Federal Clinical Research Center for Pediatric Hematology, Oncology and Immunology, one of the largest children’s cancer centers in the world performing over 300 bone marrow transplantations annually since 2012. Dr. Zhavoronkov earned two Bachelor Degrees from Queen’ s University, a Masters in Biotechnology from Johns Hopkins University and a PhD in Biophysics from the Moscow State University.

Ben Best

Mr. Best was appointed as a director of our company in July 2016. Since 2012, Mr. Best has been the Director of Research Oversight at Life Extension Foundation where he calls on his deep background and experience in cell biology and research in cancer and Alzheimer’s disease. From 2003 to 2012 Mr. Best was the President and Chief Executive Officer of Cryonics Institute. Papers published by Mr. Best include: “An Empirical Study of Some Pattern Matching Algorithms”, CIPS Congress ’85, Montreal, Quebec, Canada; “Nuclear DNA damage as a direct cause of aging” REJUVENATION RESEARCH June 2009 Vol 12, Issue 3; “Scientific justification of cryonics practice”; and “Cryoprotectant Toxicity: Facts, Issues, and Questions” REJUVENATION RESEARCH October 2016 Vol 18, Issue 5. Mr. Best maintains a collection of his personal writings including topics on the mechanisms of aging at

James Riley

Mr. Riley was appointed as a director of our company in July 2016 and brings over 20 years of leadership and investment experience in the technology industry. Mr. Riley is the CEO of, a provider of on-demand Electronic Health Record (EHR) software, which he founded in 2011 to create a cloud-based health information management service for hospitals, clinics, and physician practices. Previously, Mr. Riley founded, a cloud-based Human Capital Management provider where he acted as Chairman & CEO and led the company to customer success, analyst acclaim and product innovation that culminated in its sale in 2010. Mr. Riley received a Bachelor of Science Degree in Systems Engineering from the University of Florida and is a graduate of the Air National Guard Academy of Military Science. He served as a fighter pilot in the U.S. military and is a lifetime member of the Air Force Association.